Search results for "amine"

showing 10 items of 7299 documents

Controversies and challenges in the management of chronic urticaria

2016

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Despite the clear international guideline, there remain a number of controversies and challenges in the management of patients with chronic urticaria (CU). As a result of major advancements in urticaria over the past 4 years, the current EAACI/GA(2) LEN/EDF/WAO urticaria guideline treatment algorithm requires updating. Case studies from patients with chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], chronic inducible urticaria (CIndU) or diseases and syndromes related to CU are useful in describing and exploring chall…

AdultMalemedicine.medical_specialtyPathologyUrticariaAlternative medicineDermatologyUnmet needs030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesparasitic diseasesmedicineHumansAngioedemaDisease management (health)ChildIntensive care medicineskin and connective tissue diseasesChronic urticariaAgedbusiness.industryGuidelineMiddle AgedPedigreeCold TemperatureInfectious Diseases030228 respiratory systemChronic DiseaseHistamine H1 AntagonistsSunlightFemaleChronic idiopathic urticariabusiness
researchProduct

Lower-half facial migraine: a report of 11 cases.

2004

Purpose Vascular pain of the face constitutes a variant of pain of the head, and includes migraine, cluster headache, paroxysmal hemicrania, and a facial variant of the so-called lower-half migraine. Lower-half facial migraine is a condition difficult to classify; according to the international classifications it could not be found as an individual entity. The objective of the present study is to determine the difficulties we encountered in diagnosis, the ineffective treatments provided, and the pharmacologic treatment effect. Patients and methods A study is made of 11 cases of lower-half facial migraine, corresponding to 10 women and 1 man (mean age, 35 years), commenting on the clinical c…

AdultMalemedicine.medical_specialtyPediatricsMigraine DisordersIndomethacinCentral nervous system diseaseQuadrant (abdomen)Facial PainmedicineErgotamineMaxillaHumansParoxysmal HemicraniaVascular diseasebusiness.industryCluster headacheAnti-Inflammatory Agents Non-SteroidalAnalgesics Non-NarcoticMiddle Agedmedicine.diseaseLower halfSurgeryRoot Canal TherapyOtorhinolaryngologyMigraineTooth ExtractionErgotamineSurgeryFemaleOral Surgerybusinessmedicine.drugJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability.

2012

Previous positron emission tomography (PET) studies employing competition paradigms have shown either no change or substantial declines in striatal ( 11 C)-raclopride binding after challenge with psychotogenic doses of the N-methyl-D-aspartate antagonist ketamine. We sought to probe the relationship between the severity of ketamine-induced psychotic symptoms and altered dopamine D2/3 receptor availability throughout brain using the high affinity ligand ( 18 F)-fallypride (FP). PET recordings were obtained in a group of 10 healthy, young male volunteers, in a placebo condition, and in the course of an infusion with ketamine at a psychotomimetic dose. Administration of the Positive and Negati…

AdultMalemedicine.medical_specialtyPsychosisCaudate nucleusContext (language use)Genetics BehavioralYoung AdultInternal medicinemedicineHumansPharmacology (medical)Single-Blind MethodPharmacologyRaclopridePositive and Negative Syndrome ScaleReceptors Dopamine D2Receptors Dopamine D3Psychotomimeticmedicine.diseaseUp-RegulationPsychiatry and Mental healthEndocrinologyFallyprideSchizophreniaAnesthesiaPositron-Emission TomographyBenzamidesKetaminePsychologymedicine.drugProtein BindingThe international journal of neuropsychopharmacology
researchProduct

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

2005

Positron emission tomography (PET) studies reveal that clozapine at clinically used doses occupies less than 60% of D2/D3 dopamine receptors in human striatum. Here, the occupancy of D2/D3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. A total of 15 clozapine-treated inpatients with schizophrenia underwent a [18F]fallypride PET scan. Receptor occupancy was calculated as percent reduction in binding potential relative to unblocked values measured in seven normal volunteers. Mean D2/D3 receptor occupancy was statistically significantly higher in cortical (inferior tem…

AdultMalemedicine.medical_specialtyPsychosisPyrrolidinesDopamineStriatumBinding CompetitiveReceptors DopamineDopamine receptor D3Internal medicinemedicineHumansClozapineClozapinePharmacologyTemporal cortexDose-Response Relationship DrugChemistryReceptors Dopamine D2PutamenReceptors Dopamine D3Middle Agedmedicine.diseaseCorpus StriatumTemporal LobePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorAnesthesiaPositron-Emission TomographyBenzamidesSchizophreniaFemalemedicine.drugAntipsychotic AgentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

2000

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

AdultMalemedicine.medical_specialtyPsychosismedicine.medical_treatmentSigma receptorPanamesineDrug Administration ScheduleBasal Ganglia DiseasesPiperidinesInternal medicinemental disordersmedicineHumansReceptors sigmaAntipsychoticOxazolesBiological PsychiatryBiotransformationAgedPsychiatric Status Rating ScalesDose-Response Relationship DrugMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthEndocrinologyTreatment OutcomeTolerabilityDopamine receptorSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychiatry research
researchProduct

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT

1996

By the application of 123([123I]IBZM), an iodine-labelled dopamine D2-receptor antagonist, brain D2 receptors in humans can be visualized with single photon emission computed tomography (SPECT). The ratio of IBZM binding to striatal regions versus binding to frontal cortex (ST/FC ratio) provided a semiquantitative measurement of D2 receptor binding in the striatum. This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Prolactin levels were positively correlated with D2 receptor occupancy, reflecting at least in part a comparable dopamine receptor antagonism in different dopaminer…

AdultMalemedicine.medical_specialtyPyrrolidinesStriatumIodine RadioisotopesBenperidolProsencephalonDopamineDopamine receptor D2Internal medicinemedicineHumansReceptorClozapineTomography Emission-Computed Single-PhotonPharmacologySchizophrenia ParanoidReceptors Dopamine D2ChemistryBenperidolMiddle AgedCorpus StriatumProlactinProlactinEndocrinologymedicine.anatomical_structureDopamine receptorDopaminergic pathwaysBenzamidesDopamine AntagonistsHaloperidolAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

1999

Rationale: EMD 57445 (panamesine) is a high affinity sigma ligand with the profile of an atypical antipsychotic in animal studies. It has been reported recently to have antipsychotic activity in schizophrenia. However, its metabolite, EMD 59983, binds also to D2 and D3 dopamine (DA) receptors. Objectives: The aim of this study was to test, using single photon emission computed tomography (SPECT) and [123I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. Methods: Two IBZM SPECT-scans were performed in five neuroleptic-free schizophrenic patients (DSM IV), one befo…

AdultMalemedicine.medical_specialtyPyrrolidinesmedicine.drug_classmedicine.medical_treatmentSigma receptorAtypical antipsychoticPanamesinePharmacologychemistry.chemical_compoundIodobenzamidePiperidinesDopamine receptor D3DopamineInternal medicinemedicineHumansReceptors sigmaAntipsychoticOxazolesTomography Emission-Computed Single-PhotonPharmacologyReceptors Dopamine D2Middle AgedCorpus StriatumPyrimidinesEndocrinologychemistryBlood-Brain BarrierDopamine receptorBenzamidesSchizophreniaFemaleAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassemia major patients: a randomised clinical trial

2009

A multicentre randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone–deferoxamine (DFO–DFP) versus DFP alone to treat thalassaemia major (TM). DFP at 75 mg/kg, divided into three oral daily doses, for 4 d/week and DFO by subcutaneous infusion (8–12 h) at 50 mg/kg per day for the remaining 3 d/week was compared with DFP alone at 75 mg/kg, administered 7 d/week during a 5-year follow-up. The main outcome measures were differences between multiple observations of serum ferritin concentrations. Secondary outcomes were survival analysis, adverse events, and costs. Consecutive thalassaemia patients (275) were assessed for eligibility; 213 of these…

AdultMalemedicine.medical_specialtyRandomizationAdolescentPyridonesAdministration OralKaplan-Meier EstimateDeferoxamineInfusions SubcutaneousIron Chelating AgentsGastroenterologylaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansDeferiproneAdverse effectDecreased serum ferritinSurvival analysisbusiness.industryHematologySurgeryClinical trialDeferoxamineChelation thalassaemia clinical trials red blood cell disorders iron overload.Treatment OutcomechemistryFerritinsThalassemiaDrug Therapy CombinationFemalebusinessDeferiproneFollow-Up Studiesmedicine.drug
researchProduct

A Comparison of Five Maintenance Therapies for Reflux Esophagitis

1995

Patients with reflux esophagitis have a high rate of relapse within one year after therapy is discontinued.We enrolled 175 adults with endoscopy-confirmed reflux esophagitis in a prospective study comparing five maintenance therapies. All the patients were initially treated with omeprazole (40 mg orally once a day) for four to eight weeks, and healing was confirmed by endoscopy. Participants were then stratified according to their initial grade of esophagitis and randomly assigned to 12 months of treatment with one of the following: cisapride (10 mg three times a day), ranitidine (150 mg three times a day), omeprazole (20 mg per day), ranitidine plus cisapride (10 mg three times a day), or …

AdultMalemedicine.medical_specialtyRanitidineSeverity of Illness IndexGastroenterologyDisease-Free SurvivalRanitidinePiperidinesRecurrenceInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesReflux esophagitisProspective cohort studyEsophagitis PepticOmeprazoleCisapridemedicine.diagnostic_testEsophageal diseasebusiness.industryGeneral MedicineMiddle AgedAnti-Ulcer Agentsmedicine.diseaseSurgeryEndoscopyTreatment OutcomeHistamine H2 AntagonistsCisaprideDrug Therapy CombinationFemaleEsophagoscopybusinessEsophagitisOmeprazolemedicine.drugNew England Journal of Medicine
researchProduct

Effects of REM sleep awakenings and related wakening paradigms on the ultradian sleep cycle and the symptoms in depression.

2002

In 1975 Vogel and coworkers published their classical study where they compared selective rapid eye movement (REM) sleep deprivation by brief awakenings to a control intervention paradigm in depressed patients. The superior antidepressive impact of the first procedure was attributed to the REM pressure accumulating during the treatment period. The laborious procedure and the considerable effort necessary to evaluate the sleep profiles in real time have prevented similar experiments so far. Based on artificial neural networks we developed a software for the real time detection of REM sleep. In combination with an alarm system the algorithm allowed us to wake up subjects automatically and to …

AdultMalemedicine.medical_specialtyRapid eye movement sleepSleep REMAudiologyAntidepressive Agents TricyclicNon-rapid eye movement sleepSeverity of Illness IndexSleep Disorders Circadian RhythmSurveys and QuestionnairesmedicineHumansCircadian rhythmWakefulnessPsychiatryBiological PsychiatryUltradian rhythmSlow-wave sleepDepressionTrimipramineTrimipramineSleep in non-human animalsCircadian RhythmPsychiatry and Mental healthSleep deprivationFemalemedicine.symptomPsychologymedicine.drugJournal of psychiatric research
researchProduct